Four cases of ticlopidine-induced cholestatic hepatitis.
- Author:
Jin HAN
1
;
Moo Hyun KIM
;
Hee Kun MOON
;
Ki Tae KANG
;
Kwang Soo CHA
;
Young Dae KIM
;
Jong Seong KIM
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. kmh60@damc.or.kr
- Publication Type:Case Report
- Keywords:
Ticlopidine;
Cholestatic hepatitis;
Jaundice
- MeSH:
Coronary Artery Disease;
Coronary Vessels;
Exanthema;
Hepatitis*;
Humans;
Jaundice;
Jaundice, Obstructive;
Liver;
Stents;
Ticlopidine
- From:Korean Journal of Medicine
2002;63(5):557-561
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Ticlopidine, a potent antiplatelet agent, is widely used for treatment of coronary artery disease and cerebrovascular disease. Adverse effects has been reported in 10% to 20% of patients receiving ticlopidine. The most commom adverse effects were gastrointestinal disturbance, skin rash, but cholestatic hepatitis with jaundice was rare (0.1% incidence). We have recently experienced four cases of ticlopidine-induced cholestatic hepatitis after coronary artery stent insertion. Jaundice developed within 1 month of starting ticlopidine at recommended daily doses. In all cases, jaundice resolved and serum liver enzymes improved over a period of months after drug withdrawal. Therefore, clinicians should be aware of the reversible condition of ticlopidine-induced cholestatic jaundice that slowly resolves after drug withdrawal.
